Webinar Date: March 31, 2021
Time: 7am PT, 10am ET, 4pm MEZ
Classifying tumors by organ, such as breast or brain, ignores the genetic, biologic, and patient-related factors that make cancer cases unique. Cancer therapy is therefore moving from a one-size-fits-all paradigm to one of greater personalization. Using an in-house established platform, based on an assembly of benchtop instruments, researchers in the Remke Lab at the University of Dusseldorf Medical School have developed a system that will help guide oncologists toward the right treatments, at the right time, for the right patients.
Based on quantitative, high-throughput screening, this approach will help uncover optimal treatment choices from libraries of approved and late development-stage anticancer drugs. This highly sensitive, cell-based screening platform allows low-volume, multiple-concentration assays to support informed decision-making. The ultimate goal of this research is to enable truly personalized treatment regimens for life-threatening cancers.
You will learn about:
- A drug screening method suitable for use on patient-derived primary cancer cells
- Assay miniaturization, to 384- and 1,536-well plates using benchtop instruments
- Data analysis and visualization using Python
Who should attend:
- Cancer researchers
- Translational medical researchers
- Pharmacogenomic researchers
- Cell biologists